Why the study?
Does Mitral TEER provide similar mitral regurgitation reduction and symptom improvement in patients with significant MAC compared to those with none/mild MAC?
Does Mitral TEER provide similar mitral regurgitation reduction and symptom improvement in patients with significant MAC compared to those with none/mild MAC?
Mitral TEER is feasible and effectively reduces mitral regurgitation in patients with significant MAC, though these patients experience higher 1-year mortality and less symptom improvement compared to those with none/mild MAC.
Answers are grounded in this paper and cite their sources.
Exercise caution with mitral TEER in moderate/severe MAC; hypothesis-generating and warrants prospective trials.
=0.02, respectively). Conclusions Mitral TEER is a safe and feasible intervention in selected patients with significant MAC and associated with similar mitral regurgitation reduction at 1 year compared with patients with none/mild MAC. Patients with moderate/severe MAC had a high 1-year mortality and less improvement in their symptoms after TEER.
No takes yet. Share an insight, caveat, or question.
Hatab et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: